
## Elizabeth R Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5461746/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	6.1	23
2	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
3	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
4	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
6	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	11.3	118
7	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 2021, 12, 2893.	12.8	104
8	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. Frontiers in Immunology, 2021, 12, 763912.	4.8	5
9	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	27.8	840
10	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
11	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
12	Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein. IScience, 2020, 23, 101669.	4.1	19
13	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	6.0	121
14	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology, 2020, 160, 223-232.	4.4	86
15	Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination. Vaccine, 2019, 37, 494-501.	3.8	1
16	Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease. Vaccine, 2019, 37, 502-509.	3.8	3
17	A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Reports, 2018, 25, 3750-3758.e4.	6.4	41
18	Development of persistent gastrointestinal S. aureus carriage in mice. Scientific Reports, 2017, 7, 12415.	3.3	7

#	Article	IF	CITATIONS
19	Natural mutations in a <i>Staphylococcus aureus</i> virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3101-10.	7.1	103
20	Risk factors for dermatitis in submariners during a submerged patrol: an observational cohort study. BMJ Open, 2016, 6, e010975.	1.9	1
21	MRI Based Localisation and Quantification of Abscesses following Experimental S. aureus Intravenous Challenge: Application to Vaccine Evaluation. PLoS ONE, 2016, 11, e0154705.	2.5	2